The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus
Open accessAbstract
OBJECTIVE: In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia. METHODS: There were two main steps in the screening process. In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus. Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database. Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion (ADME) evaluation to verify that oral administration would be effective. Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV protein interaction. In the second step we searched Chinese herbal databases to identify plants containing the selected compounds. Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage. Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb. RESULTS: Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity. Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds. Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections. Network pharmacology analysis predicted that the general in vivo roles of these 26 herbal plants were related to regulating viral infection, immune/inflammation reactions and hypoxia response. CONCLUSION: Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,728
Paraskevis, D., Kostaki, E. G., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G., & Tsiodras, S. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104212 · Cited by 760
Ubiquitylation in innate and adaptive immunity
Bhoj, V. G., & Chen, Z. J. (2009) · Nature · doi:10.1038/nature07959 · Cited by 634
Identification of natural compounds with antiviral activities against SARS-associated coronavirus
LI, S., CHEN, C., ZHANG, H., GUO, H., WANG, H., WANG, L., ZHANG, X., HUA, S., YU, J., & XIAO, P. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.02.007 · Cited by 602
Self-citationWen, C.-C., Kuo, Y.-H., Jan, J.-T., Liang, P.-H., Wang, S.-Y., Liu, H.-G., Lee, C.-K., Chang, S.-T., Kuo, C.-J., Lee, S.-S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070295s · Cited by 576
Small molecules targeting severe acute respiratory syndrome human coronavirus
Wu, C.-Y., Jan, J.-T., Ma, S.-H., Kuo, C.-J., Juan, H.-F., Cheng, Y.-S. E., Hsu, H.-H., Huang, H.-C., Wu, D., Brik, A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403596101 · Cited by 521
Antiviral Activity of Glycyrrhizic Acid Derivatives against SARS−Coronavirus
Hoever, G., Baltina, L., Michaelis, M., Kondratenko, R., Baltina, L., Tolstikov, G. A., Doerr, H. W., & Cinatl, J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493008 · Cited by 416
Ratia, K., Saikatendu, K. S., Santarsiero, B. D., Barretto, N., Baker, S. C., Stevens, R. C., & Mesecar, A. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510851103 · Cited by 414
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“The results concluded that 13 existing Chinese traditional medicines were effective against novel coronavirus [69].”
ResultA role for quercetin in coronavirus disease 2019 (COVID‐19)
Derosa, G., Maffioli, P., D'Angelo, A., & Di Pierro, F. (2021) · Phytotherapy Research · doi:10.1002/ptr.6887 · Cited by 303
Di Pierro, F., Derosa, G., Maffioli, P., Bertuccioli, A., Togni, S., Riva, A., Allegrini, P., Khan, A., Khan, S., Khan, B. A., et al. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s318720 · Cited by 182
Artificial Intelligence for COVID-19: Rapid Review
(2020) · doi:10.2196/21476 · Cited by 160
Husain, I., Bala, K., Khan, I. A., & Khan, S. I. (2021) · Food Frontiers · doi:10.1002/fft2.110 · Cited by 104
Metadata
- Authors
- Zhang, D.-H., Wu, K.-L., Zhang, X., Deng, S.-Q., & Peng, B.
- Venue
- Journal of Integrative Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 18
- Issue
- 2
- Pages
- 152-158
- ISSN
- 1672-1977 (ISSN-L)
- 2095-4964
- OpenAlex
- W3006718791
- Cited by
- 482
- References
- 24
- FWCI
- 51.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. https://app.cochat.ai/papers/10.1016/j.joim.2020.02.005
- The paper
- Zhang, D.-H., Wu, K.-L., Zhang, X., Deng, S.-Q., & Peng, B. (2020). In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. Journal of Integrative Medicine. https://doi.org/10.1016/j.joim.2020.02.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
